|
|
Volumn 15, Issue 4, 2010, Pages 428-435
|
|
FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma
a
|
|
Author keywords
Mammalian target of rapamycin; mTOR; Renal cell carcinoma; Temsirolimus
|
|
Indexed keywords
ALPHA INTERFERON;
TEMSIROLIMUS;
ABDOMINAL PAIN;
ACNE;
ACUTE KIDNEY FAILURE;
ADULT;
ADVANCED CANCER;
AGED;
ANEMIA;
ANOREXIA;
ARTHRALGIA;
ARTICLE;
ASTHENIA;
BACKACHE;
CLINICAL TRIAL;
CONSTIPATION;
CONTROLLED STUDY;
COUGHING;
DIARRHEA;
DRUG APPROVAL;
DRUG ERUPTION;
DRUG INFORMATION;
DRUG RESPONSE;
DRUG SAFETY;
DRUG STRUCTURE;
DRY SKIN;
DYSGEUSIA;
DYSPNEA;
EDEMA;
EPISTAXIS;
FEMALE;
FEVER;
FOOD AND DRUG ADMINISTRATION;
HEADACHE;
HUMAN;
HYPERCHOLESTEROLEMIA;
HYPERGLYCEMIA;
HYPERLIPIDEMIA;
HYPERTRIGLYCERIDEMIA;
HYPOPHOSPHATEMIA;
INFECTION;
INSOMNIA;
INTERSTITIAL LUNG DISEASE;
INTESTINE PERFORATION;
KIDNEY CARCINOMA;
LYMPHOCYTOPENIA;
MAJOR CLINICAL STUDY;
MALE;
MUCOSA INFLAMMATION;
MULTICENTER STUDY;
NAIL DISEASE;
NAUSEA;
NEUTROPENIA;
OPEN STUDY;
OVERALL SURVIVAL;
PAIN;
PHARYNGITIS;
PHASE 3 CLINICAL TRIAL;
PNEUMONIA;
PRIORITY JOURNAL;
PROGNOSIS;
PRURITUS;
RANDOMIZED CONTROLLED TRIAL;
RHINITIS;
SIDE EFFECT;
THORAX PAIN;
THROMBOCYTOPENIA;
URINARY TRACT INFECTION;
VOMITING;
WEIGHT REDUCTION;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
DRUG APPROVAL;
FEMALE;
HUMANS;
IMMUNOLOGIC FACTORS;
INTERFERON-ALPHA;
INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS;
KIDNEY NEOPLASMS;
MALE;
MIDDLE AGED;
PROGNOSIS;
PROTEIN-SERINE-THREONINE KINASES;
SIROLIMUS;
SURVIVAL ANALYSIS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
YOUNG ADULT;
|
|
EID: 77951729433
PISSN: 10837159
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2009-0178 Document Type: Article |
|
Times cited : (202)
|
|
References (12)
|
